Emergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call Transcript

Rich Lindahl: Sure. Yeah. As I commented in my remarks, we are engaged in an active dialogue with our lender group on extending the maturity of the credit facility, the October maturity. I think I pointed to the consent to the travel health sale and the waiver that they provided is evidence that they are being constructive in those conversations. We are certainly working towards a time line to get this done as quickly as possible and we will keep you posted when we have more specific information to provide.

Boris Peaker: Great. Thanks. And then I will squeeze another one, ACAM2000. Do you have a timeframe of when we should hear about a new contract and also if a new contract is awarded, should we expect it to just cover 2023 and to be kind of a run rate historically as we have seen or should we kind of expect a bolus of catch-up for 2022 and 2023?

Bob Kramer: Yeah. Boris, great question. Our immediate interest is ensuring and finalizing the 2023 procurement decision by the U.S. Government. At the same time, we are actively in discussions with them about their longer term plans for continuing to procure ACAM as part of the strategic national stockpile requirements. So I think the answer to your question is, we are in active dialogue about both of those, both short-term and long-term. And I really can’t speculate Boris on when we expect those discussions to be finalized or to result in a procurement commitment or contract with the government.

Boris Peaker: Great. Thanks for taking my follow-up question.

Bob Kramer: Sure. Glad too. Thanks.

Operator: Thank you. I am showing no further questions, I would like to hand the conference back over to Bob Burrows for any further remarks.

Bob Burrows: Thank you, Michelle. And with that, ladies and gentlemen, we now conclude the call. Thank you for your participation. Please note an archived version of today’s webcast, as well as a PDF version of the slides used during today’s call will be made available later today and accessible through the Investors landing page on the company’s website. Thank you again and we look forward to speaking with all of you in the future. Have a good night.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.